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Changes of apoptosis-related molecules on ERK signaling pathway in KBD patients 
suggested that ERK signaling pathway might play important roles in molecular biol-
ogy mechanism of KBD, and Na2SeO3 could promote activation of pRaf-1，pMek1/2 
and pErk1/2. *This research is supported by National Natural Science Foundation 
(No. 30671820，81172610).
Muscular-skeletal DisorDers – cost studies
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BuDget iMPact of converting stanDarD treatMent of flail chest 
froM suPPortive theraPy to surgical fixation With contoureD 
titaniuM Plates in canaDian hosPitals
Hsiao C.W., Ondrejicka D.A., Goldstein L.J.
Johnson and Johnson Medical Companies, Markham, ON, Canada
Objectives: Flail chest occurs in 6-15% of patients sustaining blunt chest wall 
trauma and can be life-threatening. It is typically managed through supportive 
therapies (e.g. ventilation, pain control) but an increasing body of evidence shows 
decreased patient mortality and morbidity with rib fixation surgery. The objective 
of our study was to evaluate the budget impact of changing the treatment for flail 
chest from supportive therapy to surgical management with contoured titanium 
plates in a Canadian hospital. MethOds: A budget impact model was created using 
clinical and economic data obtained from peer-reviewed literature, the Ontario 
Case Costing Initiative and case costing data from a large Canadian hospital. A 
2013 meta-analysis was used to provide efficacy data on the reduction of health 
care resources associated with surgical management. The outcomes are reflective 
of a hospital that treats 10 patients with flail chest per year. The model takes into 
consideration costs associated with surgery, length of stay and the common com-
plications associated with flail chest. A multivariate sensitivity analysis utilizing 
a Monte Carlo simulation was conducted on economic and clinical parameters to 
ensure robustness. Results: The model found that shifting the treatment of flail 
chest from supportive to surgical management decreased the number of ventilation 
days from 13.9 to 6.4 and the total hospital stay from 27.2 to 18.4 days. It also found 
a reduction in the incidence of complications such as tracheostomies from 78.94% 
to 18% and pneumonia from 89.47% to 62%. Accounting for the additional costs 
associated with fixation devices and surgical management, the model establishes 
that surgical rib fixation for flail chest has the potential to provide a Canadian hos-
pital with an annual net cost savings of CAD$214,660. cOnclusiOns: Shifting the 
treatment of flail chest from supportive to surgical management with contoured 
titanium plates is a cost-effective solution for Canadian hospitals.
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BuDget iMPact analysis of aPixaBan versus enoxaParin in Patients 
unDergoing total hiP or knee rePlaceMent in coloMBia
Ordoñez Molina J.E.1, Garrido Lecca S.2, Vargas Zea N.3, Prieto Martinez V.4
1HEMOGROUP Hematoncology Medical Center, Medellín, Colombia, 2Bristol-Myers Squibb 
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Objectives: The aim of this analysis is to estimate the budget impact of apixaban 
compared with enoxaparin in patients undergoing total knee replacement (TKR) or 
total hip replacement (THR) in Colombia. MethOds: A model was built with a time 
horizon of five years. The comparators were: apixaban (2.5 mg BID) and enoxaparin 
(40 mg OD). The number of expected cases was calculated from the population 
census (2011) considering a growth rate of 1.2 % and an annual frequency of 0.015 
% for TKR and 0.016 % for THR, which were taken from a health insurance company 
in Colombia with over 1,800,000 affiliates nationwide. The duration of treatment for 
patients undergoing TKR (12 days) or THR (35 days) and safety data were taken from 
the literature. The analysis used the third payer perspective including direct medical 
costs and expressed in 2013 $US. The costs were taken from SISMED for drugs and 
SOAT tariff for medical procedures. Discount rate of 3 % was applied. The market 
share was estimated based on SISMED and the projected demand validated by 
expert’s opinions. Results: In a period of five years, if apixaban gets an 18 % of the 
market that currently has enoxaparin, the decrease in over total annual costs would 
be 8.8 % ($ US 5,052,857). The reduction in costs is due to fewer complications (VTE, 
pulmonary embolism and bleeding) in patients who were administered apixaban 
and a lower treatment day cost compared with enoxaparin. cOnclusiOns: The 
inclusion of apixaban in the health care reimbursement list, as thromboprophylactic 
treatment for patients undergoing TKR or THR, decreases total costs of care for the 
health system in Colombia.
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BuDget iMPact analysis of tocilizuMaB in rheuMatoiD arthritis (ra) 
in coloMBia
Gamboa O.1, Barbosa-Tovar D.2, Leon E.1, Gil A.M.1, Lozano T.1, Latorre M.C.3
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Javeriana, Bogota, Colombia
Objectives: To estimate the economic impact for Colombian health budget by 
including frontline tocilizumab used as monotherapy or in combination with 
methotrexate in patients with RA refractory to treatment with non-biologic 
DMARDs. MethOds: The population over 18 years reported by DANE, for the period 
2013-2017 was used as population risk of developing RA. This was discriminated 
by age, sex and type of affiliation. The target population were considered patients 
over 18 years with RA refractory to treatment with non-biologic DMARDs. We used 
a prevalence of 0.5% and a range for sensitivity analysis of 0.25% and 1%; the per-
centage of patients with RA using biological (4.7%) corresponded to that reported 
by literature. Intervention evaluated was: tocilizumab 8mg/Kg each 4 weeks and 
tocilizumab 8mg/Kg each 4 weeks +metotrexate 15 mg/week. Actual technology: 
adalimumab 40 mg/ sc/biweekly +metotrexate 15 mg/week; adalimumab 40 mg/ 
sc/biweekly; etanercept 50 mg/sc/week +metotrexate 15 mg/week; etanercept 
50 mg/ sc/week; infliximab 3 mg/kg IV induction regimen at 0, 2 and 6 weeks 
PMs11
theraPy With certolizuMaB Pegol anD other tnf-a inhiBitors in 
elDerly Patients With rheuMatoiD arthritis: results froM the 
corrona registry
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Objectives: To describe baseline characteristics of elderly patients with 
Rheumatoid Arthritis (RA) initiating therapy with Certolizumab Pegol ( CZP) and 
other TNF-a inhibitors (TNFi). MethOds: Cross-sectional analysis of RA patients 
older than 65 years of age, initiating CZP or another TNFi following enrollment 
in the CORRONA registry. Baseline demographic and clinical characteristics of 
included patients were assessed. Each characteristic was compared between CZP 
and other TNFi initiators using either Student’s two-sample t-test or the chi-square 
test. Results: 1062 initiations of TNFi in RA patients older than 65 years were 
analyzed; 136 (12.8%) patients initiated CZP and 926 (87.2%) another TNFi. Baseline 
characteristics for CZP initiators (versus other TNFi): age (mean±Standard devia-
tion (SD)) 72.2±6.4 (vs. 72.1±6.3, p> 0.05), female 72.8% (vs. 74.6%, p> 0.05), disease 
duration 12.1±9.9 (vs. 13.5±11.3, p> 0.05), baseline CDAI 23.8±14.4 (vs. 18.0±12.9, p: 
< 0.001), baseline mHAQ 0.50±0.51 (vs. 0.46±0.50, p> 0.05). At the time of CZP initia-
tion 45.9% of patients had high disease activity and 39.8% had moderate disease 
activity by CDAI (vs 32.8% and 33.7 respectively for other TNFi initiators, p: < 0.0001). 
Concomitant methotrexate use was present in 49.3% of CZP initiators (vs 63.3 for 
other TNFi, p 0.002). In 40.4% of CZP initiators, CZP was used after failure of two or 
more prior biologics (vs 30.2% in other TNFi initiators, p: 0.026). cOnclusiOns: 
The present descriptive analyses suggest that elderly CZP initiators have similar 
demographic characteristics with initiators of other TNFi. However, CZP is used 
more frequently after prior failure to 2 or more TNFi, is more commonly given as 
monotherapy, and initiated in patients with a higher mean disease activity com-
pared to other TNFi.
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ePiDeMiology anD Biologic treatMent Patterns of systeMic Juvenile 
iDioPathic arthritis in ontario
Al Adba B., Schneider R., Silverman E.D.
University of Toronto, Toronto, ON, Canada
Objectives: The prevalence of juvenile idiopathic arthritis (JIA) is approximately 
3.3/1000 children and 10-15% have the systemic form (SJIA). Biologics, specifically 
anti-IL1 and anti-IL6 therapy have dramatically reduced the prolonged use of cor-
ticosteroids and therefore decreased the associated morbidity including growth 
failure, cataracts, fractures and body image problems. This study aims to determine 
the prevalence of SJIA and biologic use in SJIA in Ontario. MethOds: All patients 
seen at the Rheumatology Clinic of the Hospital for Sick Children (SickKids), Toronto 
with a diagnosis of SJIA from December 1986 to January 2013 were eligible. Exclusion 
criteria: Diagnosis not confirmed, < 1 year follow-up, < 1 visit per year and unable 
to obtain complete medical record. Data for Ontario SJIA prevalence was estimated 
through personal communication with all practicing pediatric rheumatologists in 
Ontario. Results: The cohort consisted of 268 SJIA patients which represented 
13% of the total JIA cohort. Since 2012, when anti-IL-1 and anti-IL-6 medications 
were readily available in Ontario, 12/23 (52%) of newly diagnosed patients received 
either anti-IL-1 or anti-IL-6 (11/12 received anti-IL-1 therapy). In the other 3 pediatric 
rheumatology centres in Ontario, 9 additional SJIA patients were diagnosed and 3 
received anti-IL-1 and 2 anti-IL-6. Medication choice was based on the patient’s 
drug coverage, patient/parent preference for intravenous vs. subcutaneous mode 
of administration and distance from an infusion centre. No other biologic (anti-TNF 
for example) was started in any of these patients. cOnclusiOns: In Ontario there 
are approximately 150 patients with SJIA followed by pediatric rheumatologists. 
Although this group constitutes a small proportion of the total JIA population, they 
require more intensive therapy with 50% treated with a biologic as compared to 
10-15% of total all JIA patients currently followed at SickKids.
PMs13
stuDy on MechanisM of tyPe 2 DeioDinase gene anD erk signal 
transDuction in kashin-Beck Disease
Xiong Y.M., Song R.X., Jiao X.H., Du X.L., Liu J.F., Liu X., Chen Q.
Xi’an Jiaotong University, Xi’an, China
Objectives: Kashin-Beck disease (KBD) is an endemic, deformable, and chronic 
osteoarthropathy prevailing in selenium (Se)-deficiency regions, while its etiopatho-
genesis maintains obscure. Type 2 Deiodinase (DIO2) is an important Se-dependent 
antioxidant enzyme and there are many polymorphisms in DIO2 gene, among 
which, Thr92Ala，rs225014，has been studied widespread in diseases. In many dif-
ferent cells, ERK signalling pathway palys a role in anti-apoptosis and decreased ERK 
activity is necessary for apoptosis. Therefore, we investigated possible association 
between DIO2 Thr92Ala and susceptibility to KBD in a Chinese population.To explore 
molecular mechanism of cartilage apoptosis and role of Se in prevention in KBD, 
expression of signal molecules of ERK pathway in controls and KBD patients are 
detected and Na2SeO3 are added to explore it’s effect on ERK pathway. MethOds: 
218 KBD patients and 209 age and sex matched controls were enrolled and served 
as KBD and control group respectively. Polymerase Chain Reaction-Restriction 
Fragment Length Polymophism (PCR-RFLP) is used to analyze DIO2 Thr92Ala poly-
morphism. Real-Time PCR is used to detect DIO2 mRNA. Western-blot is used to 
detect expression of signal molecules of ERK transduction pathway. Results: 
No difference were found in genotypic and allelic frequency of DIO2 Thr92Ala 
between KBD and control group (P> 0.05). DIO2 mRNA level of cartilage tissue was 
significantly different between KBD and controls (P< 0.05). Expression of pRaf-1, 
pMek1/2 and pErk1/2 decreased significantly in KBD patients (0.72~, 0.78~ and 0.28 
fold respectively, P< 0.05) compared with controls. cOnclusiOns: no association 
was found between DIO2 Thr92Ala polymorphism and KBD incidence. Expression 
of DIO2 mRNA in KBD patients decreased significantly coampared with controls. 
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(IV) abatacept, adalimumab, etanercept or infliximab. MethOds: This study was 
a retrospective analysis of administrative claims data from US managed care 
plans. Patients who initiated one of the following study biologic disease modifying 
antirheumatic drugs: IV abatacept, adalimumab, etanercept or infliximab were 
identified and date of initiation was defined as the index date. The identification 
period was 7/1/2004 through 3/31/2010. Patients were required to have continu-
ous eligibility in the 6 months pre-index (baseline) period and in the 12 months 
post-index (follow-up) period, were aged ≥ 18 years at index, and had ≥ 1 baseline 
medical claim with an ICD-9-CM diagnosis code for RA (714.0x, 714.2x). Outcomes 
evaluated in the 12 month follow-up period were total health care costs (medi-
cal + pharmacy) and switch rates. Generalized Estimating Equations were used 
to compare mean change from baseline in total health care costs between the 
treatment groups. Logistic regression analysis was used to compare the odds of 
switching between treatment groups after controlling for baseline characteris-
tics. Results: The study included 8505 first-line patients and 2181 second-line 
patients. In first-line patients change from baseline in monthly total health care 
costs were higher for etanercept (Cost Ratio (CR)= 1.26; p= 0.0112), adalimumab 
(CR= 1.30; p= 0.0065) and infliximab (CR= 1.10; p= 0.3355) compared to abatacept. In 
the first-line population, after controlling for baseline covariates, etanercept (Odds 
Ratio (OR)= 2.52, 95% confidence interval (CI):1.57, 4.05), adalimumab (OR= 2.33, 95% 
CI:1.44, 3.77) and infliximab (OR= 1.91, 95% CI:1.17, 3.13) had significantly higher 
odds of switching compared to abatacept. Results for the second-line population 
were consistent with results from the first line population. cOnclusiOns: First 
or second-line abatacept patients had lowest mean change from baseline in total 
health care costs and lower rates of switching compared to adalimumab, etaner-
cept or infliximab patients.
PMs20
one-year Disease-relateD health care costs of inciDent 
osteoPorotic verteBral fractures in gerMany
Lange A.1, Zeidler J.1, Braun S.2
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Objectives: Osteoporotic vertebral compression fractures (OVCF) are among 
the most common fractures related to osteoporosis. They have been shown to be 
associated with excess mortality, and meaningful health care costs. Costs calcula-
tions have illustrated the significant financial burden to society and national social 
security systems. However, information on disease-related costs of OVCF is not 
available for Germany. Therefore, the aim of the present study was to estimate the 
direct disease-related costs of OVCF in patients with newly diagnosed fracture in 
the first year after index in Germany. MethOds: Data was obtained from a claims 
dataset of a large German health insurance fund. Subjects ≥ 60 years with a new 
vertebral fracture between 2006 - 2010 were studied retrospectively compared to a 
matched paired OVCF-free patient group. All-cause and fracture-specific medical 
costs were calculated in the 1-year baseline and follow-up period. Generalized linear 
model (GLM) was estimated for total follow-up health care cost. Results: A total of 
2,277 pairs of matched OVCF and OVCF-free patients were included in the analysis. 
Baseline costs were higher in the OVCF group. Mean unadjusted all-cause health 
care cost difference in the 4 quarters following the index date between OVCF and 
OVCF-free patients was 8,200 € (p< 0.001). Of the difference, almost two-third was 
attributable to inpatient services and one-quarter to prescription drug costs. The 
GLM procedure revealed that OVCF-related costs in the first year after the index date 
add up to 6,490 € (p< 0.001; CI: 5,809 € - 6,731 € ). cOnclusiOns: Despite limitations 
of this study, including sensitivity and specificity of claims-based diagnoses, and 
generalizability issues, our results are consistent with other research and dem-
onstrate that OVCF’s are associated with significant costs. In light of the high and 
increasing incidence and prevalence of these fractures, the results emphasize the 
importance of research in this field.
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non-invasive exogen ultrasonic treateMent of non-healing 
fractures leaDs to DecreaseD costs coMPareD to surgery
Mehta S1, Long K.2, Smith E.3, Coyle K.2, DeKoven M.3
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Objectives: The cost associated with fracture care exceeds $21 billion. Yet, not all 
fractures heal, leading to even further expenses. There is an economic and societal 
burden to surgical treatment. The purpose of this study is to compare the costs 
associated with surgical treatment versus non-invasive methods in managing non-
unions (fractures that have not healed). MethOds: A retrospective cohort direct 
match study was performed using administrative claims (integrated medical and 
pharmacy data) from the IMS LifeLinkÔ Health Plan Claims Database. All patients 
with at least one claim for EXOGEN® Ultrasound Bone Healing System (non-invasive) 
or non-union surgery were identified between April 1, 2007 and March 31, 2010; data 
through March 31, 2011 were used. Results: 1,158 matched patients were selected 
(579 in ‘Exogen Only’ and 579 in ‘Surgery Only’ cohorts). Over the 12 month post-
index period, the Surgery Only cohort had higher mean total all-cause direct medical 
costs compared to the Exogen Only cohort ($25,850 vs. $18,813; p < 0.0001). Mean 
outpatient costs accounted for over 50% of the total all-cause overall costs in both 
cohorts and were significantly higher among the Surgery Only cohort compared to 
the Exogen Only cohort ($13,964 vs. $11,072; p < 0.0001). Total mean all-cause inpa-
tient costs were also significantly higher among the Surgery Only cohort compared 
to the Exogen Only cohort ($9,612 vs $5,298; p < 0.0001). Non-union fracture-related 
mean direct medical costs were over 126% higher in the Surgery Only group versus 
the Exogen Only group ($11,276 vs. $4,987; p < ,0.0001). cOnclusiOns: Compared 
to surgery only, the use of Exogen only for the treatment of non-union fractures 
resulted in significant cost savings which could amount to $4 billion dollars annually 
in the US alone. Additional research is needed to further quantify true costs (both 
direct and indirect) as well as the cost-effectiveness of two treatment modalities 
while monitoring outcomes.
followed by a maintenance every 8 week + metotrexate 15 mg/week. This analysis 
was development for perspective of third payer. Only direct costs was used in the 
model: sourced drug acquisition and administration costs. Results: Inclusion 
of tocilizumab does not imply additional costs to the Colombian health system 
and may even save resources by 17 million dollars until 2017. In the probabil-
istic model, tocilizumab has a thrifty impact in most years. This model shows 
that yhe inclusion of Tocilizumab saves costs for the Colombian health sys-
tem (with increases of the inclusion, more saves) versus capitation payment 
unit (UPC). cOnclusiOns: Inclusion of tocilizumab to mandatory health plan 
Colombia, would have an impact thrifty indicating that the health budget would 
not increase with inclusion.
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cost of tuMor necrosis factor inhiBitors anD treatMent Patterns 
aMong MeDicaiD Beneficiaries With rheuMatoiD arthritis
Bonafede M.M.1, Joseph G.2, Shah N.3, Princic N.1, Harrison D.J.3
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Objectives: To estimate annual cost-per-treated patient and treatment patterns for 
etanercept, adalimumab, and infliximab in Medicaid beneficiaries with Rheumatoid 
Arthritis (RA). MethOds: The MarketScan Medicaid Multistate Database was used 
to identify adult RA patients indexing on etanercept, adalimumab, or infliximab 
from 2007-2011. The index date was the first index agent claim preceded by 180 days 
and followed by 360 days of continuous enrollment. Patients with conditions other 
than RA were excluded. “Continuing” patients had ≥ 1 claim in the 180 days pre-
index for their index biologic; “new” patients did not. Cost per treated patient was 
calculated in the 360 day post-index period for each index agent as the total index 
drug and administration costs to the payer and the costs of switched-to agents, 
divided by the number of patients who received the index agent. Costs were based 
on the amount of drug used (mg) multiplied by the September 2013 Wholesale 
Acquisition Cost. Treatment patterns were also described. Results: A total of 1,085 
patients met the study criteria: 48% received etanercept (n= 521); 37% received adali-
mumab (n= 405); and 15% received infliximab (n= 159). Patient characteristics were 
similar across treatment groups (mean age 47.4 years, 83% female). The annual cost 
per treated patient was lowest for etanercept ($18,466), followed by adalimumab 
($20,983) and infliximab ($26,516). For all agents, annual costs were lower for new 
patients ($17,996 for etanercept, $18,992 for adalimumab, and $24,756 for infliximab) 
than for continuing patients ($19,004 for etanercept, $24,438 for adalimumab, and 
$28,127 for infliximab). Rates of index drug discontinuation (including switching) 
were 43.8%, 46.2%, and 50.0% for etanercept, adalimumab, and infliximab; switching 
rates were 17.5%, 20.2%, and 31.0%, respectively. cOnclusiOns: Etanercept had 
a lower cost per treated patient compared with adalimumab or infliximab in both 
new and continuing patients among Medicaid enrollees with RA.
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Patients initiating first or seconD-line suBcutaneous aBatacePt, 
aDaliMuMaB, or etancercePt: a Difference-in-Difference analysis
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Objectives: There are no published data on health care costs among rheumatoid 
arthritis (RA) patients treated with subcutaneous abatacept. This study compared 
health care costs between RA patients initiating subcutaneous abatacept or one of 
the two most commonly-used subcutaneous anti-tumor necrosis factor-α agents, 
adalimumab and etanercept. MethOds: Retrospective cohort study using a large 
U.S. administrative claims database. Patients included for study had initiated subcu-
taneous abatacept, adalimumab, or etanercept between 1/1/2009-10/1/2012 (index), 
were continuously enrolled for 12 months before (baseline) and ≥ 3 months after 
index, were aged ≥ 18 years at index, and had ≥ 1 baseline medical claim with an 
ICD-9-CM diagnosis code for RA (714.0x). First-line initiators used no biologic pre 
index; second-line initiators used only one biologic pre index. A follow-up period 
extended from index until the first occurrence of switch to another biologic, dis-
enrollment from health insurance, or 12/31/2012. Total health care costs (medical 
+ pharmacy) were measured during baseline and follow-up on a per-patient-per-
month basis. Health care costs were compared using a difference-in-difference (DID) 
analysis [(abatacept $post–abatacept $pre)–(comparator $post–comparator $pre)] 
with Generalized Estimating Equations applied to a two-period (baseline/follow-up) 
panel dataset. A priori-defined sensitivity analyses examined costs when ending 
follow-up at a gap in therapy ≥ 200% of the longest labeled retreatment interval 
for the initiated biologic. Results: The study included 163 abatacept, 7,098 adali-
mumab, and 8,776 etanercept first-line patients; 256 abatacept, 2,055 adalimumab, 
1,303 etanercept second-line patients. In all analyses, abatacept had the numerically 
lowest health care costs, with differences often being statistically significant (first-
line DID: adalimumab= $640, p= 0.0012 // etanercept= $657, p= 0.0010; second-line 
DID: adalimumab= $120, p= 0.0425 // etanercept= $94, p= 0.1304). Sensitivity analyses 
produced consistent results. cOnclusiOns: In this study of RA patients initiating 
first or second-line subcutaneous abatacept, adalimumab, or etanercept, patients 
initiating subcutaneous abatacept had the lowest health care costs according to 
the DID estimator.
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health care costs anD sWitching in Patients initiating Biologic 
Disease MoDifying antirheuMatic Drugs
Nadkarni A.1, You M.2, Graham J.P.1
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Objectives: The objectives of this study were to compare health care costs and 
switch rates between rheumatoid arthritis (RA) patients initiating intravenous 
